drugset / Trial / NCT05514054
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Timeline
- Start
- 2022-10-04
- Primary completion
- 2027-10
- Completion
- 2032-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Anastrozole | Other / unclassified | — | — |
| Comparator | Exemestane | Small molecule | — | — |
| Subject | Imlunestrant | Small molecule | — | Oral |
| Comparator | Letrozole | Other / unclassified | — | — |
| Comparator | Tamoxifen | Small molecule | — | — |